GO:0004619 phosphoglycerate mutase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004619 phosphoglycerate mutase activity catalyzes the reversible interconversion of (2R)-2-phosphoglycerate and (2R)-3-phosphoglycerate, a step in glycolysis and gluconeogenesis.
• The reaction is essential for ATP generation and metabolic reprogramming in cancer cells, often upregulated in the Warburg effect.
• PGAM1, the main human phosphoglycerate mutase, also has non-glycolytic roles in DNA damage repair and ferroptosis regulation.
• PGAM5, a mitochondrial phosphatase, regulates inflammation and cell death via dephosphorylation of Bax and other substrates.
• Small-molecule inhibitors of PGAM1 show promise in cancer therapy, including synergy with immunotherapy.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are powerful tools to dissect PGAM function in health and disease.
Description
Phosphoglycerate mutase activity (GO:0004619) is a fundamental enzymatic function in the glycolytic pathway, responsible for the reversible conversion of 2-phosphoglycerate to 3-phosphoglycerate. This reaction is critical for cellular energy production and metabolic homeostasis, and its dysregulation is implicated in various diseases, including cancer and inflammatory conditions. Understanding the molecular mechanism, regulation, and disease relevance of phosphoglycerate mutase activity is essential for researchers in metabolism, oncology, and cell biology. This article provides a comprehensive overview based on authoritative QuickGO data and verified PubMed literature, highlighting key genes, experimental models, and research methods.
phosphoglycerate mutase activity At A Glance
| GO ID | GO:0004619 |
|---|---|
| GO term | phosphoglycerate mutase activity |
| Ontology | molecular_function |
| Synonym | PGAM activity, PGA mutase activity, phosphoglyceromutase activity |
| Definition | Catalysis of the reaction: (2R)-2-phosphoglycerate = (2R)-3-phosphoglycerate. |
| Major function | Glycolytic/gluconeogenic interconversion of phosphoglycerates |
| EC number | 5.4.2.11 (2,3-bisphosphoglycerate-dependent) and 5.4.2.12 (2,3-bisphosphoglycerate-independent) |
| Cofactor | 2,3-bisphosphoglycerate (for dependent form) |
| Subcellular location | Cytosol (PGAM1), mitochondria (PGAM5) |
What Is GO:0004619?
Phosphoglycerate mutase activity (GO:0004619) is defined as the catalysis of the reaction: (2R)-2-phosphoglycerate = (2R)-3-phosphoglycerate. This enzymatic activity facilitates the intramolecular transfer of a phosphate group, a key step in glycolysis and gluconeogenesis. The term encompasses both 2,3-bisphosphoglycerate-dependent and -independent forms, also known as PGAM activity or phosphoglyceromutase activity.
Why Is phosphoglycerate mutase activity Important in Cell Biology?
Phosphoglycerate mutase activity is central to glucose metabolism, and its dysregulation is a hallmark of metabolic reprogramming in cancer, where it supports rapid ATP production and biosynthesis. Beyond glycolysis, PGAM1 and PGAM5 have emerged as multifunctional proteins involved in DNA repair, apoptosis, and inflammation, making them attractive targets for therapeutic intervention. Understanding this activity is therefore crucial for developing novel treatments for cancer, inflammatory diseases, and metabolic disorders.
• Essential for glycolysis and gluconeogenesis, maintaining cellular energy balance.
• Upregulated in many cancers, contributing to the Warburg effect and tumor growth.
• PGAM1 regulates DNA damage repair via WIP1, affecting genomic stability.
• PGAM1 inhibition induces ferroptosis and enhances anti-PD-1 immunotherapy in hepatocellular carcinoma.
• PGAM5 triggers inflammation in acute kidney injury by dephosphorylating Bax.
• Allosteric inhibitors of PGAM1 show potential in colon cancer treatment.
• Fructose-1,6-bisphosphate acts as a phosphate donor to activate PGAM1, linking metabolism to signaling.
• Phosphoglycerate mutase activity is a potential biomarker and therapeutic target in multiple diseases.
What Happens During phosphoglycerate mutase activity?
Substrate Binding and Phosphate Transfer
In simple terms: The enzyme grabs a phosphate group from one molecule and moves it to another position.
Phosphoglycerate mutase binds 2-phosphoglycerate and transfers a phosphate group from its active-site histidine (in the dependent form) or via a metal ion (in the independent form) to produce 3-phosphoglycerate. This reversible reaction is a key step in glycolysis and gluconeogenesis.
Role of 2,3-Bisphosphoglycerate as Cofactor
In simple terms: A helper molecule called 2,3-BPG is needed for the enzyme to work in its dependent form.
The 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase requires 2,3-BPG as a cofactor, which phosphorylates the active-site histidine, enabling the enzyme to catalyze the reaction. The independent form uses metal ions instead.
Regulation by Metabolites
In simple terms: Other molecules can turn the enzyme on or off.
Fructose-1,6-bisphosphate has been shown to act as a phosphate donor to activate PGAM1, revealing a novel regulatory mechanism linking glycolysis intermediates to enzyme activity.
Non-Glycolytic Functions
In simple terms: The enzyme can do more than just glycolysis.
PGAM1 regulates DNA damage repair by modulating WIP1 activity, and PGAM5 dephosphorylates Bax to trigger mitochondrial DNA release and inflammation. These functions expand the biological importance of phosphoglycerate mutase activity beyond metabolism.
Key Genes Involved in GO:0004619 phosphoglycerate mutase activity
The following genes encode proteins with phosphoglycerate mutase activity or are closely related to its function.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PGAM1 | Main glycolytic phosphoglycerate mutase in cytosol | Cancer metabolism, DNA repair, ferroptosis |
| PGAM2 | Muscle-specific phosphoglycerate mutase | Muscle metabolism, glycogen storage disorders |
| PGAM5 | Mitochondrial phosphatase with phosphoglycerate mutase fold | Inflammation, apoptosis, acute kidney injury |
| BPGM | Bisphosphoglycerate mutase, produces 2,3-BPG | Oxygen transport, hemoglobin regulation |
| ENO1 | Enolase, adjacent glycolytic enzyme | Glycolysis, cancer |
| PKM | Pyruvate kinase, downstream glycolytic enzyme | Cancer metabolism, Warburg effect |
| LDHA | Lactate dehydrogenase, converts pyruvate to lactate | Anaerobic glycolysis, cancer |
| HIF1A | Hypoxia-inducible factor, regulates glycolytic genes | Cancer, hypoxia response |
| TP53 | Tumor suppressor, regulates metabolism | Cancer, DNA repair |
| WIP1 (PPM1D) | Phosphatase regulated by PGAM1 | DNA damage response |
| BAX | Pro-apoptotic protein dephosphorylated by PGAM5 | Apoptosis, inflammation |
| GAPDH | Glyceraldehyde-3-phosphate dehydrogenase | Glycolysis, cancer |
| PGK1 | Phosphoglycerate kinase, adjacent glycolytic enzyme | Glycolysis, cancer |
| SLC2A1 (GLUT1) | Glucose transporter | Glucose uptake, cancer |
| HK2 | Hexokinase 2, first glycolytic enzyme | Cancer metabolism |
| PDK1 | Pyruvate dehydrogenase kinase, regulates TCA cycle | Cancer metabolism |
| MYC | Oncogene, drives glycolytic gene expression | Cancer |
How Is phosphoglycerate mutase activity Regulated?
Phosphoglycerate mutase activity is regulated at multiple levels. PGAM1 can be activated by fructose-1,6-bisphosphate, which acts as a phosphate donor. Its expression is often upregulated in cancer via oncogenic signaling pathways such as HIF-1 and MYC, contributing to the Warburg effect. Additionally, PGAM5 activity is regulated by mitochondrial stress and proteolytic cleavage, influencing cell death and inflammation.
phosphoglycerate mutase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PGAM1 | Hepatocellular carcinoma, ferroptosis | PGAM1 knockout HCC cell lines, xenograft models |
| PGAM1 | Colon cancer, TAM-mediated progression | PGAM1 allosteric inhibitor in colon cancer models |
| PGAM5 | Acute kidney injury, inflammation | PGAM5 knockout mice, renal tubular cells |
| PGAM1 | DNA damage repair, cancer | PGAM1 knockout cells with DNA damage agents |
| PGAM1 | Metabolic reprogramming, Warburg effect | Cancer cell lines with PGAM1 overexpression or knockdown |
Cancer Metabolism and Progression
Phosphoglycerate mutase activity is frequently upregulated in cancers, supporting the Warburg effect and tumor growth. PGAM1 inhibition promotes ferroptosis in hepatocellular carcinoma and synergizes with anti-PD-1 immunotherapy. In colon cancer, an allosteric inhibitor of PGAM1 restrains tumor-associated macrophage-mediated progression. These findings highlight PGAM1 as a therapeutic target.
Inflammation and Acute Kidney Injury
PGAM5 initiates inflammation in acute kidney injury by dephosphorylating the pro-apoptotic protein Bax, leading to mitochondrial DNA release. This pathway links phosphoglycerate mutase activity to sterile inflammation and tissue damage.
DNA Damage Repair and Genomic Stability
PGAM1 activates DNA damage repair by regulating WIP1 activity, thereby influencing genomic stability and cancer cell survival after DNA damage. This non-glycolytic function expands the role of phosphoglycerate mutase in tumor biology.
Liver Inflammation and Cell Death
Decoding cell death signals in liver inflammation has revealed complex roles for metabolic enzymes, including phosphoglycerate mutase, in hepatocyte death and inflammation. Further research is needed to fully elucidate these mechanisms.
From phosphoglycerate mutase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the role of PGAM1 in cancer cell proliferation? | PGAM1 knockout cell lines (e.g., HeLa, HCT116) |
| How does PGAM1 regulate DNA damage repair? | PGAM1 knockout cells treated with DNA-damaging agents |
| Does PGAM5 dephosphorylation of Bax drive inflammation? | PGAM5 knockout mice and renal tubular cells |
| Can PGAM1 inhibition synergize with immunotherapy? | Mouse tumor models with PGAM1 inhibitor and anti-PD-1 |
| What is the effect of PGAM1 allosteric inhibition on colon cancer? | Colon cancer xenografts treated with PGAM1 inhibitor |
| How does fructose-1,6-bisphosphate regulate PGAM1? | In vitro enzymatic assays and cellular models |
How to Study the phosphoglycerate mutase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic activity assay | Conversion of 2-PG to 3-PG | Kinetic studies, inhibitor screening |
| CRISPR knockout screen | Gene essentiality and synthetic lethality | Identifying regulators of PGAM1 inhibitor sensitivity |
| Thermal proteome profiling | Protein-ligand interactions and stability | Discovering metabolites that activate PGAM1 |
| Metabolic flux analysis | Glycolytic flux and metabolite levels | Assessing Warburg effect in cancer cells |
| Western blot | Protein expression and phosphorylation | Validating PGAM1/PGAM5 knockout or overexpression |
| Immunofluorescence | Subcellular localization | Determining mitochondrial localization of PGAM5 |
| RNA-seq | Transcriptional changes | Evaluating global effects of PGAM1 inhibition |
| Xenograft tumor models | In vivo tumor growth | Testing PGAM1 inhibitors and immunotherapies |
Enzymatic Activity Assays
Phosphoglycerate mutase activity can be measured using coupled enzymatic assays that monitor the conversion of 2-phosphoglycerate to 3-phosphoglycerate, often linked to NADH oxidation. These assays are essential for validating inhibitors and studying kinetics.
CRISPR-Cas9 Knockout Screens
Genome-wide CRISPR knockout screens can identify genes that modulate sensitivity to PGAM1 inhibitors or regulate phosphoglycerate mutase activity, revealing synthetic lethal interactions.
Proteomics and Thermal Proteome Profiling
Thermal proteome profiling has been used to identify fructose-1,6-bisphosphate as a phosphate donor that activates PGAM1, demonstrating the power of proteomics in discovering novel regulatory mechanisms.
Metabolic Flux Analysis
Isotope tracing and metabolic flux analysis can quantify glycolytic flux and the contribution of phosphoglycerate mutase activity to central carbon metabolism in cancer cells.
How CRISPR Can Be Used to Study GO:0004619 phosphoglycerate mutase activity
Knockout
CRISPR-Cas9 knockout of PGAM1 or PGAM5 allows researchers to study loss-of-function phenotypes, such as reduced glycolytic flux, impaired DNA repair, or altered inflammatory responses. Knockout cell lines are valuable for validating drug targets and understanding gene function.
Point Mutation
Introducing point mutations in the active site of PGAM1 (e.g., histidine to alanine) can abolish enzymatic activity, enabling precise dissection of catalytic versus non-catalytic functions. Such models help distinguish glycolytic from non-glycolytic roles.
Knock-in
Knock-in of tagged PGAM1 (e.g., FLAG or GFP) allows for affinity purification, imaging, and interactome studies. Knock-in of disease-associated mutations can model human disorders linked to phosphoglycerate mutase dysfunction.
Overexpression
Overexpression of PGAM1 or PGAM5 via CRISPR activation or lentiviral vectors can mimic the upregulated state observed in cancers, facilitating studies on metabolic reprogramming, drug resistance, and tumorigenesis.
How EDITGENE Supports phosphoglycerate mutase activity Research
Researchers studying phosphoglycerate mutase activity-related genes often need to determine whether a candidate gene is causally involved in metabolic reprogramming, cancer progression, or inflammation. EDITGENE provides comprehensive CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for phosphoglycerate mutase activity research.
Frequently Asked Questions About phosphoglycerate mutase activity
What is phosphoglycerate mutase activity?
Phosphoglycerate mutase activity (GO:0004619) is the enzymatic catalysis of the reversible conversion of 2-phosphoglycerate to 3-phosphoglycerate, a key step in glycolysis and gluconeogenesis.
What genes are involved in phosphoglycerate mutase activity?
The main genes are PGAM1 (cytosolic), PGAM2 (muscle-specific), and PGAM5 (mitochondrial), each encoding proteins with phosphoglycerate mutase or related phosphatase activity.
How is phosphoglycerate mutase activity regulated?
It is regulated by metabolites such as fructose-1,6-bisphosphate, which acts as a phosphate donor to activate PGAM1, and by oncogenic signaling pathways that upregulate expression.
What diseases are associated with phosphoglycerate mutase dysfunction?
Dysregulation is linked to cancer (e.g., hepatocellular carcinoma, colon cancer), acute kidney injury, and inflammatory conditions.
What is the role of PGAM1 in cancer?
PGAM1 supports the Warburg effect, DNA damage repair, and ferroptosis resistance, making it a therapeutic target in multiple cancers.
How can CRISPR be used to study phosphoglycerate mutase activity?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of PGAM genes to study their functions in metabolism, cancer, and inflammation.
What methods measure phosphoglycerate mutase activity?
Enzymatic activity assays, metabolic flux analysis, and thermal proteome profiling are commonly used to measure and study this activity.
Is PGAM5 a phosphoglycerate mutase?
PGAM5 has a phosphoglycerate mutase fold but functions primarily as a protein phosphatase, regulating inflammation and apoptosis.
What are the therapeutic implications of targeting phosphoglycerate mutase?
Inhibitors of PGAM1 show promise in cancer therapy, including synergy with immunotherapy, and may be useful in inflammatory diseases.
What is the Warburg effect and how does it relate to phosphoglycerate mutase?
The Warburg effect is the increased reliance on glycolysis in cancer cells, often involving upregulated phosphoglycerate mutase activity to support rapid growth.
Conclusion
Phosphoglycerate mutase activity (GO:0004619) is a cornerstone of cellular metabolism with expanding roles in cancer, inflammation, and DNA repair. The integration of CRISPR-based models and advanced omics technologies is accelerating our understanding of this enzyme family. Targeting phosphoglycerate mutase activity holds promise for novel therapeutics in oncology and beyond.
References
- 1. Brenner C et al.. 2013. Decoding cell death signals in liver inflammation.. J Hepatol 59(3):583-94 PMID: 23567086
- 2. Zhang Y et al.. 2024. Thermal proteome profiling reveals fructose-1,6-bisphosphate as a phosphate donor to activate phosphoglycerate mutase 1.. Nat Commun 15(1):8936 PMID: 39414782
- 3. Li J et al.. 2023. Phosphoglycerate mutase 5 initiates inflammation in acute kidney injury by triggering mitochondrial DNA release by dephosphorylating the pro-apoptotic protein Bax.. Kidney Int 103(1):115-133 PMID: 36089186
- 4. Winn SI et al.. 1981. Structure and activity of phosphoglycerate mutase.. Philos Trans R Soc Lond B Biol Sci 293(1063):121-30 PMID: 6115412
- 5. Wang C et al.. 2024. A phosphoglycerate mutase 1 allosteric inhibitor restrains TAM-mediated colon cancer progression.. Acta Pharm Sin B 14(11):4819-4831 PMID: 39664444
- 6. Ohba S et al.. 2020. Phosphoglycerate Mutase 1 Activates DNA Damage Repair via Regulation of WIP1 Activity.. Cell Rep 31(2):107518 PMID: 32294440
- 7. Zheng Y et al.. 2023. PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti-PD-1 Immunotherapy.. Adv Sci (Weinh) 10(29):e2301928 PMID: 37705495
- 8. Fukushi A et al.. 2022. Revisited Metabolic Control and Reprogramming Cancers by Means of the Warburg Effect in Tumor Cells.. Int J Mol Sci 23(17) PMID: 36077431
